Pancreatic fluid interleukin-1β complements prostaglandin E2 and serum carbohydrate antigen 19-9 in prediction of intraductal papillary mucinous neoplasm dysplasia

Rachel E. Simpson, Michele Yip-Schneider, Katelyn F. Flick, Huangbing Wu, Cameron L. Colgate, C. Schmidt

Research output: Contribution to journalArticle

Abstract

Objectives We sought to determine if interleukin (IL)-1β and prostaglandin E2 (PGE2) (inflammatory mediators in pancreatic fluid) together with serum carbohydrate antigen (CA) 19-9 could better predict intraductal papillary mucinous neoplasm (IPMN) dysplasia than individual biomarkers alone. Methods Pancreatic cyst fluid (n = 92) collected via endoscopy or surgery (2003-2016) was analyzed for PGE2 and IL-1β (enzyme-linked immunosorbent assay). Patients had surgical pathology-proven IPMN. Threshold values (PGE2 [>1100 pg/mL], IL-1β [>20 pg/mL], and serum CA 19-9 [>36 U/mL]) were determined. Results Levels of IL-1β were higher in high-grade dysplasia (HGD)/invasive-IPMN (n = 42) compared with low/moderate IPMN (n = 37) (median [range], 54.6 [0-2671] vs 5.9 [0-797] pg/mL; P < 0.001; area under curve [AUC], 0.766). Similarly, PGE2 was higher in HGD/invasive IPMN (n = 45) compared with low/moderate IPMN (n = 47) (median [range], 1790 [20-15,180] vs. 140 [10-14,630] pg/mL; P < 0.001; AUC, 0.748). Presence of elevated PGE2 and IL-1β (AUC, 0.789) provided 89% specificity and 82% positive predictive value (PPV) for HGD/invasive IPMN. Elevated levels of all 3 provided 100% specificity and PPV for HGD/invasive IPMN. Conclusions Cyst fluid PGE2, IL-1β, and serum CA 19-9 in combination optimize specificity and PPV for HGD/invasive IPMN and may help build a panel of markers to predict IPMN dysplasia.

Original languageEnglish (US)
Pages (from-to)1026-1031
Number of pages6
JournalPancreas
Volume48
Issue number8
DOIs
StatePublished - Sep 1 2019

Fingerprint

Interleukin-1
Dinoprostone
Carbohydrates
Antigens
Serum
Neoplasms
Area Under Curve
Cyst Fluid
Pancreatic Cyst
Surgical Pathology
Endoscopy
Biomarkers
Enzyme-Linked Immunosorbent Assay

Keywords

  • biomarker
  • dysplasia
  • interleukin-1β
  • intraductal papillary mucinous neoplasm
  • pancreatic cyst
  • prostaglandin E2

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Pancreatic fluid interleukin-1β complements prostaglandin E2 and serum carbohydrate antigen 19-9 in prediction of intraductal papillary mucinous neoplasm dysplasia. / Simpson, Rachel E.; Yip-Schneider, Michele; Flick, Katelyn F.; Wu, Huangbing; Colgate, Cameron L.; Schmidt, C.

In: Pancreas, Vol. 48, No. 8, 01.09.2019, p. 1026-1031.

Research output: Contribution to journalArticle

@article{0f62a6d5e22043ea86b636ed5e181c63,
title = "Pancreatic fluid interleukin-1β complements prostaglandin E2 and serum carbohydrate antigen 19-9 in prediction of intraductal papillary mucinous neoplasm dysplasia",
abstract = "Objectives We sought to determine if interleukin (IL)-1β and prostaglandin E2 (PGE2) (inflammatory mediators in pancreatic fluid) together with serum carbohydrate antigen (CA) 19-9 could better predict intraductal papillary mucinous neoplasm (IPMN) dysplasia than individual biomarkers alone. Methods Pancreatic cyst fluid (n = 92) collected via endoscopy or surgery (2003-2016) was analyzed for PGE2 and IL-1β (enzyme-linked immunosorbent assay). Patients had surgical pathology-proven IPMN. Threshold values (PGE2 [>1100 pg/mL], IL-1β [>20 pg/mL], and serum CA 19-9 [>36 U/mL]) were determined. Results Levels of IL-1β were higher in high-grade dysplasia (HGD)/invasive-IPMN (n = 42) compared with low/moderate IPMN (n = 37) (median [range], 54.6 [0-2671] vs 5.9 [0-797] pg/mL; P < 0.001; area under curve [AUC], 0.766). Similarly, PGE2 was higher in HGD/invasive IPMN (n = 45) compared with low/moderate IPMN (n = 47) (median [range], 1790 [20-15,180] vs. 140 [10-14,630] pg/mL; P < 0.001; AUC, 0.748). Presence of elevated PGE2 and IL-1β (AUC, 0.789) provided 89{\%} specificity and 82{\%} positive predictive value (PPV) for HGD/invasive IPMN. Elevated levels of all 3 provided 100{\%} specificity and PPV for HGD/invasive IPMN. Conclusions Cyst fluid PGE2, IL-1β, and serum CA 19-9 in combination optimize specificity and PPV for HGD/invasive IPMN and may help build a panel of markers to predict IPMN dysplasia.",
keywords = "biomarker, dysplasia, interleukin-1β, intraductal papillary mucinous neoplasm, pancreatic cyst, prostaglandin E2",
author = "Simpson, {Rachel E.} and Michele Yip-Schneider and Flick, {Katelyn F.} and Huangbing Wu and Colgate, {Cameron L.} and C. Schmidt",
year = "2019",
month = "9",
day = "1",
doi = "10.1097/MPA.0000000000001377",
language = "English (US)",
volume = "48",
pages = "1026--1031",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Pancreatic fluid interleukin-1β complements prostaglandin E2 and serum carbohydrate antigen 19-9 in prediction of intraductal papillary mucinous neoplasm dysplasia

AU - Simpson, Rachel E.

AU - Yip-Schneider, Michele

AU - Flick, Katelyn F.

AU - Wu, Huangbing

AU - Colgate, Cameron L.

AU - Schmidt, C.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objectives We sought to determine if interleukin (IL)-1β and prostaglandin E2 (PGE2) (inflammatory mediators in pancreatic fluid) together with serum carbohydrate antigen (CA) 19-9 could better predict intraductal papillary mucinous neoplasm (IPMN) dysplasia than individual biomarkers alone. Methods Pancreatic cyst fluid (n = 92) collected via endoscopy or surgery (2003-2016) was analyzed for PGE2 and IL-1β (enzyme-linked immunosorbent assay). Patients had surgical pathology-proven IPMN. Threshold values (PGE2 [>1100 pg/mL], IL-1β [>20 pg/mL], and serum CA 19-9 [>36 U/mL]) were determined. Results Levels of IL-1β were higher in high-grade dysplasia (HGD)/invasive-IPMN (n = 42) compared with low/moderate IPMN (n = 37) (median [range], 54.6 [0-2671] vs 5.9 [0-797] pg/mL; P < 0.001; area under curve [AUC], 0.766). Similarly, PGE2 was higher in HGD/invasive IPMN (n = 45) compared with low/moderate IPMN (n = 47) (median [range], 1790 [20-15,180] vs. 140 [10-14,630] pg/mL; P < 0.001; AUC, 0.748). Presence of elevated PGE2 and IL-1β (AUC, 0.789) provided 89% specificity and 82% positive predictive value (PPV) for HGD/invasive IPMN. Elevated levels of all 3 provided 100% specificity and PPV for HGD/invasive IPMN. Conclusions Cyst fluid PGE2, IL-1β, and serum CA 19-9 in combination optimize specificity and PPV for HGD/invasive IPMN and may help build a panel of markers to predict IPMN dysplasia.

AB - Objectives We sought to determine if interleukin (IL)-1β and prostaglandin E2 (PGE2) (inflammatory mediators in pancreatic fluid) together with serum carbohydrate antigen (CA) 19-9 could better predict intraductal papillary mucinous neoplasm (IPMN) dysplasia than individual biomarkers alone. Methods Pancreatic cyst fluid (n = 92) collected via endoscopy or surgery (2003-2016) was analyzed for PGE2 and IL-1β (enzyme-linked immunosorbent assay). Patients had surgical pathology-proven IPMN. Threshold values (PGE2 [>1100 pg/mL], IL-1β [>20 pg/mL], and serum CA 19-9 [>36 U/mL]) were determined. Results Levels of IL-1β were higher in high-grade dysplasia (HGD)/invasive-IPMN (n = 42) compared with low/moderate IPMN (n = 37) (median [range], 54.6 [0-2671] vs 5.9 [0-797] pg/mL; P < 0.001; area under curve [AUC], 0.766). Similarly, PGE2 was higher in HGD/invasive IPMN (n = 45) compared with low/moderate IPMN (n = 47) (median [range], 1790 [20-15,180] vs. 140 [10-14,630] pg/mL; P < 0.001; AUC, 0.748). Presence of elevated PGE2 and IL-1β (AUC, 0.789) provided 89% specificity and 82% positive predictive value (PPV) for HGD/invasive IPMN. Elevated levels of all 3 provided 100% specificity and PPV for HGD/invasive IPMN. Conclusions Cyst fluid PGE2, IL-1β, and serum CA 19-9 in combination optimize specificity and PPV for HGD/invasive IPMN and may help build a panel of markers to predict IPMN dysplasia.

KW - biomarker

KW - dysplasia

KW - interleukin-1β

KW - intraductal papillary mucinous neoplasm

KW - pancreatic cyst

KW - prostaglandin E2

UR - http://www.scopus.com/inward/record.url?scp=85071311407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071311407&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000001377

DO - 10.1097/MPA.0000000000001377

M3 - Article

C2 - 31404023

AN - SCOPUS:85071311407

VL - 48

SP - 1026

EP - 1031

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 8

ER -